Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO)

Hartmann JT, Issels RD, Nicolo KS, Gruenwald V, Hertenstein B, Papesch E, Krause S, Sturm I (2015)

Publication Type: Journal article

Publication year: 2015

Journal

Investigational New Drugs Springer Verlag (Germany)

Publisher: Springer Verlag (Germany)

Book Volume: 33

Pages Range: 1115-22

Journal Issue: 5

DOI: 10.1007/s10637-015-0267-x

Abstract

To assess the efficacy and safety of topotecan and cyclophosphamide (TC) in adult patients with pediatric-type sarcoma subtypes who failed induction chemotherapy.Patients with pediatric sarcoma subtypes, refractory to or relapsed after at least one prior induction chemotherapy, inoperable, ECOG PS 0-2, with measurable, progressive disease (PD), adequate organ functions, who have been treated with TC combination were retrospectively analysed within the AIO and SAREZ/BMBF network.Thirty-nine patients, median age 28 years (18-58), 14 females, 25 males, have been identified. All patients had received induction treatment according to (inter)national study protocols. Second-line TC was applied in 33 patients (>=3rd-line in 6 patients). Twenty-three patients had refractory disease (evidence of PD during induction chemotherapy); 8 patients experienced an early relapse within 6 months as well as 8 patients after more than 24 months (late relapse). A median of 3 cycles (range, 1-6) had been applied and antitumor activity was: CR 2.6 %, PR 7.9 %, and disease stabilisation (SD) 26.3 %. PR lasted 32.8 months and median duration in patients with SD was 5 months (range, 2.0-14.7). The 3/6-months progression-free rates were 43.2 and 18.9 %.Limited activity was seen in adult pts with refractory or relapsed pediatric-type sarcomas with the regimen which has proven activity in pediatric patients. Adults with refractory small cell sarcoma appear to have a similar dismal outcome as seen in pts with common adult-type histologies; however, a subset of patients has achieved long-lasting remissions on TC resulting in long-term survival.

Authors with CRIS profile

Stefan Krause Department of Medicine 5 – Haematology and Oncology

Involved external institutions

Charité - Universitätsmedizin Berlin DE Germany (DE) Franziskus Hospital Bielefeld DE Germany (DE) Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Medizinische Hochschule Hannover (MHH) / Hannover Medical School DE Germany (DE) Klinikverbund Bremen (Gesundheit Nord) DE Germany (DE) Universitätsmedizin der Johannes Gutenberg-Universität Mainz DE Germany (DE)

How to cite

APA:

Hartmann, J.T., Issels, R.D., Nicolo, K.S., Gruenwald, V., Hertenstein, B., Papesch, E.,... Sturm, I. (2015). Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO). Investigational New Drugs, 33(5), 1115-22. https://doi.org/10.1007/s10637-015-0267-x

MLA:

Hartmann, Joerg Thomas, et al. "Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO)." Investigational New Drugs 33.5 (2015): 1115-22.

BibTeX: Download